U.S. Patent Office issues Notice of Allowance for Kuros' PTH to improve bone healing

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has received Notice of Allowance for U.S. 11/679,807 from the U.S. Patent Office. The now allowed application acknowledges that Kuros has been first in showing that parathyroid hormone (PTH) when applied locally in a matrix to a bone defect has the ability to improve bone healing. Kuros has already demonstrated the clinical utility of this proprietary approach to bone healing in two large phase II studies in trauma patients which have reported previously.

Kuros is developing a portfolio of biomaterial, and bioactive-biomaterial combination, products. The Company's product candidates are based on two different matrix technology platforms.  Kuros' most advanced products are based on a fibrin matrix and include KUR-111 and KUR-113 which have achieved positive results in large Phase II trials for tibial plateau fractures and tibial shaft fractures respectively.

 Didier Cowling, Chief Executive Officer at Kuros says: "This patent will give Kuros broad protection on the concept of locally applied PTH to improve bone healing. Obtaining the notice of allowance for this US patent application further builds on Kuros' proprietary position in local treatments for bone generation and healing".

The Notice of Allowance for US 11/679,807 with its broad scope of protection follows US 7,247,609, US 6,331,422, US 6,607,740, EP 1 465 989, EP 1 124 590, EP 1 280 566 and patents in many other countries which protect Kuros` approach with PTH and its incorporation into matrices for local therapeutic applications.

SOURCE Kuros Biosurgery AG